Suppr超能文献

SETDB1 三重结构域结合配体,(,)-59,促进细胞中 Akt1 的甲基化。

SETDB1 Triple Tudor Domain Ligand, (,)-59, Promotes Methylation of Akt1 in Cells.

机构信息

UNC Eshelman School of Pharmacy, Center for Integrative Chemical Biology and Drug Discovery, Chemical Biology and Medicinal Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Department of Biochemistry and Biophysics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

出版信息

ACS Chem Biol. 2023 Aug 18;18(8):1846-1853. doi: 10.1021/acschembio.3c00280. Epub 2023 Aug 9.

Abstract

Increased expression and hyperactivation of the methyltransferase SET domain bifurcated 1 (SETDB1) are commonly observed in cancer and central nervous system disorders. However, there are currently no reported SETDB1-specific methyltransferase inhibitors in the literature, suggesting that this is a challenging target. Here, we disclose that the previously reported small-molecule ligand for SETDB1's triple tudor domain, (,)-59, is unexpectedly able to increase SETDB1 methyltransferase activity both and in cells. Specifically, (,)-59 promotes SETDB1-mediated methylation of lysine 64 of the protein kinase Akt1. Treatment with (,)-59 also increased Akt1 threonine 308 phosphorylation and activation, a known consequence of Akt1 methylation, resulting in stimulated cell proliferation in a dose-dependent manner. (,)-59 is the first SETDB1 small-molecule positive activator for the methyltransferase activity of this protein. Mechanism of action studies show that full-length SETDB1 is required for significant methylation of an Akt1-K64 peptide and that this activity is stimulated by (,)-59 primarily through an increase in catalytic activity rather than a change in -adenosyl methionine binding.

摘要

在癌症和中枢神经系统疾病中,通常观察到甲基转移酶 SET 结构域分裂 1(SETDB1)的表达增加和过度激活。然而,目前文献中没有报道 SETDB1 特异性甲基转移酶抑制剂,这表明这是一个具有挑战性的靶点。在这里,我们披露了先前报道的 SETDB1 的三串联结构域的小分子配体(,)-59,出乎意料地能够增加 和细胞中 SETDB1 甲基转移酶活性。具体而言,(,)-59 促进了蛋白激酶 Akt1 的赖氨酸 64 残基的 SETDB1 介导的甲基化。(,)-59 的处理还增加了 Akt1 苏氨酸 308 磷酸化和激活,这是 Akt1 甲基化的已知后果,导致细胞增殖以剂量依赖的方式受到刺激。(,)-59 是第一个 SETDB1 小分子蛋白甲基转移酶活性的阳性激活剂。作用机制研究表明,全长 SETDB1 是 Akt1-K64 肽显著甲基化所必需的,并且这种活性主要通过增加催化活性而不是 -腺苷甲硫氨酸结合的变化来被(,)-59 刺激。

相似文献

本文引用的文献

4
Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer.PI3K/AKT/mTOR通路的激活导致乳腺癌耐药。
Front Pharmacol. 2021 Mar 15;12:628690. doi: 10.3389/fphar.2021.628690. eCollection 2021.
7
Histone lysine methyltransferases in biology and disease.生物学和疾病中的组蛋白赖氨酸甲基转移酶。
Nat Struct Mol Biol. 2019 Oct;26(10):880-889. doi: 10.1038/s41594-019-0298-7. Epub 2019 Oct 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验